Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,501,763 claiming composition of matter for VS-4718, the Company’s novel, small molecule inhibitor of cancer stem cells through blockade of focal adhesion kinase (FAK). The U.S. patent grants coverage of VS-4718 into 2029. Corresponding patent applications are pending in major markets throughout the world including Europe, Japan, Australia and Canada.
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,501,763 claiming composition of matter for VS-4718, the Company’s novel, small molecule inhibitor of cancer stem cells through blockade of focal adhesion kinase (FAK). The U.S. patent grants coverage of VS-4718 into 2029. Corresponding patent applications are pending in major markets throughout the world including Europe, Japan, Australia and Canada.
Help employers find you! Check out all the jobs and post your resume.
